Table 2.
|
|
Fold change, control vs. treatments |
|||
---|---|---|---|---|---|
Probe set ID | Gene title | Gene symbol | TNF alone | DC + TNF | C95 + TNF |
1552277_a_at | Transmembrane protein with EGF-like and two follistatin-like domains 1 | C9orf30 | 2.6 | 2.3 | 2 |
1552914_a_at | CD276 molecule | CD276 | 8.9 | 5.3 | 3.1 |
1559064_at | Nucleoporin, 153 kDa | NUP153 | 4.4 | 4.7 | 3.7 |
201502_s_at | Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha | NFKBIA | 6.8 | 6.4 | 5.9 |
203921_at | Carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2 | CHST2 | 3.4 | 2.6 | 2 |
205476_at | Chemokine (C-C motif) ligand 20 | CCL20 | 181.3 | 181.6 | 162.6 |
207937_x_at | Fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) | FGFR1 | 2.1 | 1.5 | 0.8 |
208711_s_at | Cyclin D1 | CCND1 | 4.6 | 4 | 3.4 |
211924_s_at | Plasminogen activator, urokinase receptor | PLAUR | 4.5 | 3.9 | 3.5 |
216074_x_at | WW and C2 domain containing 1 | WWC1 | 41.8 | 58.4 | 8.5 |
219488_at | α1,4-Galactosyltransferase (globotriosylceramide synthase) | A4GALT | 3 | 2.5 | 2.1 |
220353_at | Family with sequence similarity 86, member C | FAM86C | 2.2 | 2.1 | 1.3 |
220382_s_at | Rho GTPase activating protein 28 | ARHGAP28 | 4.2 | 4.3 | 3.9 |
221530_s_at | Basic helix-loop-helix domain containing, class B, 3 | BHLHB3 | 5.5 | 4.7 | 3.7 |
226142_at | GLI pathogenesis-related 1 (glioma) | GLIPR1 | 2.2 | 2.3 | 1.9 |
226281_at | Delta/notch-like EGF repeat containing | DNER | 2.2 | 2 | 1.9 |
227340_s_at | RGM domain family, member B | RGMB | 2.4 | 2.4 | 2.3 |
235417_at | SPOC domain containing 1 | SPOCD1 | 4.9 | 4.3 | 3.6 |
238417_at | Phosphoglucomutase 2-like 1 | PGM2L1 | 2.2 | 1.8 | 1.4 |
238532_at | D4, zinc and double PHD fingers, family 3 | DPF3 | 3.2 | 2.3 | 1.7 |
Data presented indicate fold change in gene expression compared with TNF-α-untreated control group. Probe set ID, Affymetrix probe identifications. Supplement for Fig. 8, cluster C.